Benefit of Latanoprostene Bunod (Vyzulta) for Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Cohort Study in Taiwan

INTRODUCTION: ) in Taiwanese patients with glaucoma who were switched from conventional PGAs. METHODS: The records of patients treated at Kaohsiung Veterans General Hospital with glaucoma who were switched to LBN from conventional PGAs between November 2020 and December 2021 were retrospectively reviewed. IOP measurements were taken at baseline, 1 month, 3 months, and 6 months, and 1 year after switching. Outcomes included changes in IOP from baseline at each follow-up period, and adverse event evaluation. Repeated measures analysis of variance (ANOVA) tests and the generalized estimating equations (GEE) analyses were performed to estimate the effect of LBN on IOP reduction over time. RESULTS: A total of 87 patients (129 eyes) were included. Significant IOP reduction trends were noted across various subgroups, including patients with different initial IOP and different glaucoma types. GEE analysis showed significant IOP reductions in most subgroups, with the greatest reduction observed in patients with high initial IOP (estimate = -4.59, 95% confidence interval [CI] -6.9 to -3.0, p < 0.001). Adverse events occurred in 18% of patients, all of which were mild. CONCLUSIONS: In this retrospective cohort of Taiwanese patients with glaucoma whose IOP remained inadequately controlled on prior PGAs therapy, switching to LBN was associated with a statistically significant, although modest, reduction in IOP over 12 months and a low rate of mild, non-serious ocular adverse events. These exploratory real-world findings provide hypothesis-generating evidence supporting LBN as a treatment option when further IOP reduction is needed and should be confirmed in larger prospective multicenter studies.